US pharma major Eli Lilly has followed up last year’s $1.4 billion acquisition of radiopharmaceuticals firm POINT Biopharma Global with another deal in the field. 2 July 2024
A co-development deal between Finland’s Orion Corporation (HEL: ORNAV) and Merck & Co (NYSE: MRK) has been upgraded to an exclusive global licensing agreement. 1 July 2024
Oncology small molecule specialist Redx Pharma (JPJ: REDX) has announced positive mid-stage results from the Phase II PORCUPINE and PORCUPINE2 studies of zamaporvint. 1 July 2024
Johnson & Johnson (NYSE: JNJ) has received a new European approval for a combination of Rybrevant (amivantamab) plus chemotherapy in lung cancer. 28 June 2024
TwoStep Therapeutics, a biotech start-up developing targeted therapies for solid tumors, has officially launched after securing $6.5 million in seed funding. 27 June 2024
CASI Pharmaceuticals (Nasdaq: CASI) has announced a preliminary proposal from its chairman and chief executive, Wei-Wu He, to acquire the company's business operations in China. 27 June 2024
Germany’s Merck KGaA (MRK: DE) has pulled the plug on its Phase III TrilynX study, evaluating xevinapant plus chemo in head and neck cancer. 25 June 2024
Deal volume was up 20% in the pharmaceutical and life sciences sector in the last 12 months as dealmakers grew more comfortable with uncertainty, according to a 21 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.